Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie TARSILA Real-World Evidence (TARSILA)

2 listopada 2026 zaktualizowane przez: Maicon Falavigna, Inova Medical

Skuteczność rzeczywista szczepienia maTernAl RSVpreF przeciwko zakażeniom RSV związanym z ostrą chorobą układu oddechowego u niemowląt w BrAzil (badanie TARSILA): wieloośrodkowe, prospektywne, testowo-ujemne badanie kliniczno-kontrolne

The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.

Przegląd badań

Szczegółowy opis

Tarsila comprises two multicenter, prospective, case-control studies using a test-negative design in Southern Brazil (states of Rio Grande do Sul, Santa Catarina, and Paraná). The Tarsila Inpatient study will enroll infants hospitalized due to acute respiratory illness and will be conducted at referral hospitals. The Tarsila Outpatient study will enroll infants with acute respiratory illness managed in outpatient settings and will be conducted at outpatient healthcare facilities. Both studies are aligned with the nationwide introduction of maternal RSVpreF vaccination in December 2025, with enrollment occurring from April, 2026 to September, 2028. In both studies, the same clinical case definition will be applied to cases and controls. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for RSV will be prospectively performed to classify case infants (RT-qPCR positive for RSV) and control infants (RT-qPCR negative for RSV). Maternal RSVpreF vaccination status and potential confounders will be assessed through structured interviews and review of medical records.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

5000

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Paraná
      • Cascavel, Paraná, Brazylia, 85818-130
        • Rekrutacyjny
        • Unidade de Pronto Atendimento Veneza
        • Kontakt:
      • Curitiba, Paraná, Brazylia, 80060-900
        • Rekrutacyjny
        • Complexo do Hospital de Clínicas da Universidade Federal do Paraná
        • Kontakt:
        • Główny śledczy:
          • Cristina de Oliveira Rodrigues
      • Curitiba, Paraná, Brazylia, 80240-031
        • Rekrutacyjny
        • Hospital Infantil Pequeno Príncipe
        • Kontakt:
        • Główny śledczy:
          • Heloisa Ihle Garcia Giamberardino
      • Marechal Cândido Rondon, Paraná, Brazylia, 85960-000
        • Rekrutacyjny
        • Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel
        • Kontakt:
      • Palotina, Paraná, Brazylia, 85950-000
        • Rekrutacyjny
        • Unidade de Saúde Central de Palotina
        • Kontakt:
      • Toledo, Paraná, Brazylia, 85902-480
        • Rekrutacyjny
        • Unidade de Pronto Atendimento II de Toledo
        • Kontakt:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazylia, 91350-200
        • Rekrutacyjny
        • Hospital Nossa Senhora da Conceição
        • Kontakt:
        • Główny śledczy:
          • Fernanda H Varela
      • Porto Alegre, Rio Grande do Sul, Brazylia, 90035-903
        • Rekrutacyjny
        • Hospital de Clínicas de Porto Alegre
        • Kontakt:
        • Główny śledczy:
          • Ricardo Becker Feijó

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

Nie starszy niż 11 miesięcy (Dziecko)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Infants with acute respiratory illness (ARI)

Opis

Tarsila Inpatient Study

Inclusion Criteria

  • Infant born in Brazil.
  • Mother resident in Brazil during the related pregnancy.
  • Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
  • Infant ≤360 days of age at time of RSV specimen collection.
  • Infant born at ≥37 weeks of gestational age.
  • Infant hospital admission for at least 24 hours with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Exclusion Criteria:

  • Maternal or infant receipt of any other licensed or investigational RSV preventive product.
  • Infant receipt of blood transfusion or other blood products containing antibodies since birth.
  • Infant previously enrolled in this study.
  • Lack of informed consent from the mother or the infant's legal guardian.
  • Absent or inconclusive RT-qPCR result for RSV.
  • Birth to a mother whose RSVpreF vaccination status could not be confirmed.

Tarsila Outpatient Study

Inclusion Criteria:

  • Infant born in Brazil.
  • Mother resident in Brazil during the related pregnancy.
  • Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
  • Infant ≤360 days of age at time of RSV specimen collection.
  • Infant born at ≥37 weeks of gestational age.
  • Infant presentation to an outpatient healthcare facility with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Exclusion Criteria:

  • Mother or infant receipt of any other licensed or investigational RSV preventive product.
  • Infant receipt of blood transfusion or other blood products containing antibodies since birth.
  • Lack of informed consent from the mother or the infant's legal guardian.
  • Absent or inconclusive RT-qPCR result for RSV.
  • Birth to a mother whose RSVpreF vaccination status could not be confirmed.
  • Enrollment in the study within the previous 30 days. If the interval exceeds 30 days, infants will be excluded if any previous episode tested positive for RSV.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: CASE_CONTROL
  • Perspektywy czasowe: PROSPECTIVE

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Cases

Infants with a positive respiratory syncytial virus result on a nasal swab specimen

For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

Controls

Infants with a negative respiratory syncytial virus result on a nasal swab specimen

For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth

Hospitalization due to RT-qPCR-confirmed RSV-positive lower respiratory tract disease, defined as cough or difficulty breathing, symptom onset within the preceding 10 days, and at least one of the following: tachypnea (respiratory rate ≥60 breaths/min for infants <2 months; ≥50 breaths/min for infants 2-12 months), oxygen saturation (SpO₂) <95%, or chest wall indrawing).

Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)
Ramy czasowe: Occurring ≤180 days after birth.

RT-qPCR-confirmed RSV-positive with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Occurring ≤180 days after birth.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:

  • Gestational age at RSVpreF vaccination.
  • Time from RSVpreF vaccination to birth.
  • Time intervals of infant age at illness.
Hospitalization occurring ≤180 days after birth
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, defined as LRTD plus at least one of the following: respiratory rate ≥70 breaths/min (if <2 months) or ≥60 breaths/min (if ≥2 months); SpO₂ <93%; requirement for high-flow oxygen, non-invasive, or invasive mechanical ventilation; intensive care unit (ICU) admission for >4 hours; or unresponsiveness/loss of consciousness) .

Hospitalization occurring ≤180 days after birth
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, analyzed by:

  • Gestational age at RSVpreF vaccination.
  • Time from RSVpreF vaccination to birth.
  • Time intervals of infant age at illness.
Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up to 180 days by Subgroups (Tarsila Outpatient Study)
Ramy czasowe: ARI occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by: gestational age at RSVpreF vaccination, time from RSVpreF vaccination to birth, and time intervals of infant age at illness.

ARI occurring ≤180 days after birth

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
Hospitalization occurring ≤180 days after birth
Lower respiratory Tract Disease (LRTD) ICU hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization

RT-qPCR-confirmed RSV-positive LRTD ICU hospitalization. ICU admission occuring at any point during the index hospitalization.

Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
Lower respiratory Tract Disease (LRTD) prolonged hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD long hospital stay (≥11 days) .

Hospitalization occurring ≤180 days after birth
Lower respiratory Tract Disease (LRTD) in-hospital death among infants aged up to 180 days (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.

RT-qPCR-confirmed RSV-positive LRTD in-hospital death.

Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
Hospitalization for lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by time intervals of infant age at illness.

Hospitalization occurring ≤360 days after birth
Severe lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
Hospitalization occurring ≤180 days after birth
Hospitalization for severe lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by time intervals of infant age at illness.

Hospitalization occurring ≤360 days after birth
Acute respiratory illness (ARI) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI hospitalization

Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) hospitalization among infants aged up to 360 days (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive ARI hospitalization.

Hospitalization occurring ≤360 days after birth
Lower respiratory Tract Disease (LRTD) Hospitalization due to Human Metapneumovirus (HMPV) among infants aged up to 180 days (Tarsila Inpatient Study)
Ramy czasowe: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed HMPV-positive LRTD hospitalization

Hospitalization occurring ≤180 days after birth
Acute Respiratory Illness (ARI) among infants aged up to 180 days by exploratory subgroups (Tarsila Outpatient Study)
Ramy czasowe: ARI occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
ARI occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up 360 days (Tarsila Outpatient Study)
Ramy czasowe: ARI occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by time intervals of infant age at illness.

ARI occurring ≤360 days after birth
Lower respiratory Tract Disease (LRTD) among infants aged up to 180 days (Tarsila Outpatient Study)
Ramy czasowe: LRTD occurring ≤180 days after birth.

RT-qPCR-confirmed RSV-positive LRTD.

LRTD occurring ≤180 days after birth.
Lower respiratory Tract Disease (LRTD) infants aged up to 360 days (Tarsila Outpatient Study)
Ramy czasowe: LRTD occurring ≤360 days after birth.

RT-qPCR-confirmed RSV-positive LRTD.

LRTD occurring ≤360 days after birth.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Maicon Falavigna, Inova Medical

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

27 kwietnia 2026

Zakończenie podstawowe (Szacowany)

30 września 2028

Ukończenie studiów (Szacowany)

31 grudnia 2028

Daty rejestracji na studia

Pierwszy przesłany

20 lutego 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

25 lutego 2026

Pierwszy wysłany (Rzeczywisty)

3 marca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

4 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIEZDECYDOWANY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj